Search

Displaying results 1981 - 1990 of 8974 in total
  1. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    [A20302] Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather … Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.

  2. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.

    Categories: Antihypertensives for Pulmonary Arterial Hypertension
  3. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Antidepressive Agents Indicated for Depression
  4. Drug

    Methadone

    go.drugbank.com/drugs/DB00333
    ApprovedInvestigational

    Use of OAT is also intended to lead to social stabilization by reducing crime rates, incarceration, use of illicit opioids such as [heroin] or [fentanyl], and ultimately marginalization. … [F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes such as neuropathic pain and cancer

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.

    Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaSynonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETH
  6. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. … [T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of

  7. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies.

  8. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

  9. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [A247265] On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory

    Categories: Biologics for Rheumatoid Arthritis Treatment
  10. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).